ARS Pharmaceuticals, Inc. (SPRY): Results of Operations and Financial Condition
ARS Pharmaceuticals, Inc. (SPRY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results $26.2 million in U.S. neffy ® net product revenue in Q2 2026; total U.S. epinephrine market share for Type 1 allergies of 5%
How this was made
The 30-second read
Why it matters
Traders can update models for 2H 2026 operating expense expectations, reassess runway using the reported cash balance, and reprice clinical optionality based on the expected Q1 2027 interim data for the CSU Phase 2b trial.
Market read
Primary filing with concrete Q2 financials, cash balance, 2H expense guidance, and commercial KPIs, plus a near-term catalyst in the form of today’s call and a clinical interim-data window.
What to watch
SG&A remains high in absolute terms and the 2H expense range includes stock-based compensation; investors may focus on cash burn trajectory versus the stated path to cash-flow breakeven by end of 2027.
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
Product revenue, net was $26,210 (in thousands), compared with $12,800 (in thousands), while total revenue was $33,658 (in thousands), compared with $15,717 (in thousands). However, total operating expenses were $95,123 (in thousands), net loss was $(62,339) (in thousands), and cash, cash equivalents, and short-term investments were $143.8 million as of June 30, 2026.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Product revenue, netGAAP | $26,210 (in thousands) | – | – |
| Revenue under collaboration agreementsGAAP | $57 (in thousands) | – | – |
| Revenue under supply agreementsGAAP | $7,391 (in thousands) | – | – |
| Total revenueGAAP | $33,658 (in thousands) | – | – |
| Cost of goods soldGAAP | $12,846 (in thousands) | – | – |
| Research and developmentGAAP | $4,698 (in thousands) | – | – |
| Selling, general and administrativeGAAP | $77,579 (in thousands) | – | – |
| Total operating expenses excluding cost of goods soldother | $82.3 million | – | – |
| Total operating expensesGAAP | $95,123 (in thousands) | – | – |
| Loss from operationsGAAP | $(61,465) (in thousands) | – | – |
| Interest incomeGAAP | $1,605 (in thousands) | – | – |
| Interest expenseGAAP | $(2,479) (in thousands) | – | – |
| Total other (expense) income, netGAAP | $(874) (in thousands) | – | – |
| Net lossGAAP | $(62,339) (in thousands) | – | – |
| Unrealized losses on available-for-sale securitiesGAAP | $(44) (in thousands) | – | – |
| Comprehensive lossGAAP | $(62,383) (in thousands) | – | – |
| Net loss per share, basic and dilutedGAAP | $(0.63) | – | – |
| Weighted-average shares outstanding used in computing net loss per share, basic and dilutedGAAP | 99,312,526 | – | – |
| Six-month product revenue, netGAAP | $43,662 (in thousands) | – | – |
| Six-month revenue under collaboration agreementsGAAP | $2,546 (in thousands) | – | – |
| Six-month revenue under supply agreementsGAAP | $10,131 (in thousands) | – | – |
| Six-month total revenueGAAP | $56,339 (in thousands) | – | – |
| Six-month cost of goods soldGAAP | $19,132 (in thousands) | – | – |
| Six-month research and developmentGAAP | $9,034 (in thousands) | – | – |
| Six-month selling, general and administrativeGAAP | $149,783 (in thousands) | – | – |
| Six-month total operating expensesGAAP | $177,949 (in thousands) | – | – |
| Six-month loss from operationsGAAP | $(121,610) (in thousands) | – | – |
| Six-month net lossGAAP | $(122,957) (in thousands) | – | – |
| Six-month comprehensive lossGAAP | $(123,222) (in thousands) | – | – |
| Six-month net loss per share, basic and dilutedGAAP | $(1.24) | – | – |
| Six-month weighted-average shares outstanding used in computing net loss per share, basic and dilutedGAAP | 99,304,512 | – | – |
| Total U.S. epinephrine market share for Type 1 allergiesother | 5% | – | a doubling |
| Market share among field-targeted accountsother | 8% | – | – |
| Unique prescribersother | Over 16,000 | – | a nearly threefold increase |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Product revenue, netnet product revenue from neffy sales in the United States | $26,210 (in thousands) | – | – |
| Revenue under collaboration agreementscollaboration revenue from international partners | $57 (in thousands) | – | – |
| Revenue under supply agreementssupply revenue from partners | $7,391 (in thousands) | – | – |
Second half of 2026 outlook
- Operating expensesaggregate SG&A and R&D expenses in the range of $114 million to $126 million
- Notestock-based compensation expense of approximately $14 million to $16 million
- Notetotal cash-based SG&A and R&D expenses in the range of $100 million to $110 million
- Notemore than 40% reduction in SG&A cash-based expenses from the first half of 2026
- Notefavorable trend planned to continue through full-year 2027
- Notepath to reaching cash flow breakeven by the end of 2027
- Noteinterim Phase 2b data in the first quarter of 2027
What drove it
- U.S. net product revenue was $26.2 million in the second quarter, and 2026 year-to-date net product revenue was $43.7 million.
- Total U.S. epinephrine market share for Type 1 allergies was 5%, compared with 2.5% in the same period in 2025.
- Market share was 8% among field-targeted accounts, compared with 4% in the same period in 2025.
- Sales force efforts will focus primarily on the highest-value prescribers, which represent 44% of the total U.S. market opportunity.
- SG&A expenses were primarily driven by consumer-targeted media activities incurred before the updated operating plan, sales force expansion, and one-time personnel-related expenses related to the July leadership transition.
- R&D expenses were primarily related to the ongoing Phase 2b trial in CSU and registry study and continuing development and regulatory expenses.
Concerns
- The company reported a net loss of $(62,339) (in thousands) and loss from operations of $(61,465) (in thousands).
- Total operating expenses were $95,123 (in thousands), including $77,579 (in thousands) of selling, general and administrative expense.
- Cash, cash equivalents, and short-term investments were $143.8 million as of June 30, 2026, compared with $244,986 (in thousands) of cash and cash equivalents plus short-term investments at December 31, 2025.
- Term loans, net were $96,676 (in thousands), and financing liability was $74,927 (in thousands), at June 30, 2026.
- Interim CSU Phase 2b data are expected in the first quarter of 2027.
What to watch
- Execution of the shift from broad consumer-directed marketing to targeted engagement with high-volume prescribers.
- Progress in total U.S. epinephrine market share and market share among field-targeted accounts.
- Delivery of aggregate SG&A and R&D expenses in the range of $114 million to $126 million for the second half of 2026.
- The anticipated more than 40% reduction in SG&A cash-based expenses from the first half of 2026.
- Interim data from the CSU Phase 2b trial in the first quarter of 2027.
- Progress toward the anticipated path to cash flow breakeven by the end of 2027.
Balance sheet and cash flow
- Cash and cash equivalents were $8,163 (in thousands) at June 30, 2026 and $41,317 (in thousands) at December 31, 2025.
- Short-term investments were $135,682 (in thousands) at June 30, 2026 and $203,669 (in thousands) at December 31, 2025.
- Cash, cash equivalents, and short-term investments were $143.8 million as of June 30, 2026.
- Accounts receivable, net were $46,839 (in thousands) at June 30, 2026 and $25,347 (in thousands) at December 31, 2025.
- Inventories were $11,689 (in thousands) at June 30, 2026 and $8,369 (in thousands) at December 31, 2025; noncurrent inventories were $19,045 (in thousands) and $23,053 (in thousands), respectively.
- Total assets were $249,495 (in thousands) at June 30, 2026 and $327,652 (in thousands) at December 31, 2025.
- Term loans, net were $96,676 (in thousands) at June 30, 2026 and $96,374 (in thousands) at December 31, 2025.
- Financing liability was $74,927 (in thousands) at June 30, 2026 and $72,140 (in thousands) at December 31, 2025.
- Total liabilities were $236,983 (in thousands) at June 30, 2026 and $213,394 (in thousands) at December 31, 2025.
- Total stockholders’ equity was $12,512 (in thousands) at June 30, 2026 and $114,258 (in thousands) at December 31, 2025.
Analysis
ARS Pharma reported expanding neffy commercial activity in the second quarter. Product revenue, net was $26,210 (in thousands), compared with $12,800 (in thousands), while total revenue was $33,658 (in thousands), compared with $15,717 (in thousands). The company cited total U.S. epinephrine market share for Type 1 allergies of 5%, compared with 2.5% in the same period in 2025, and 8% share among field-targeted accounts, compared with 4%. It also reported over 16,000 unique prescribers, a nearly threefold increase over the same period in 2025.
The revenue mix included $26,210 (in thousands) of product revenue, net, $57 (in thousands) of revenue under collaboration agreements, and $7,391 (in thousands) of revenue under supply agreements. Cost of goods sold was $12,846 (in thousands). The release does not report gross profit or gross margin, so the filing does not provide a stated measure of product economics after cost of goods sold.
Spending remained elevated during the quarter. Selling, general and administrative expense was $77,579 (in thousands), which the company said was primarily driven by consumer-targeted media activities incurred before its updated operating plan, sales force expansion, and one-time personnel-related costs related to the July leadership transition. R&D was $4,698 (in thousands), primarily related to the ongoing CSU Phase 2b trial, registry study, and development and regulatory expense. Total operating expenses were $95,123 (in thousands), producing a loss from operations of $(61,465) (in thousands) and net loss of $(62,339) (in thousands), or $(0.63) per share basic and diluted.
Management is redirecting commercial investment from broad consumer advertising toward targeted provider engagement and states that the field sales organization expansion is complete. Second-half guidance calls for aggregate SG&A and R&D expense of $114 million to $126 million, including approximately $14 million to $16 million of stock-based compensation expense, and cash-based SG&A and R&D expense of $100 million to $110 million. The company expects a more than 40% reduction in SG&A cash-based expenses from the first half of 2026 and anticipates a path to cash flow breakeven by the end of 2027.
Liquidity and the expense reset are central to the outlook. ARS Pharma reported $143.8 million in cash, cash equivalents, and short-term investments as of June 30, 2026, alongside $96,676 (in thousands) of term loans, net, and $74,927 (in thousands) of financing liability. The next clinical catalyst cited is interim CSU Phase 2b data in the first quarter of 2027. Management views ARS-2 as an expansion opportunity that could use existing commercial infrastructure and overlapping targeted prescribers, if approved.
Management, verbatim
Today, we are announcing a shift in focus to provider adoption, with a more efficient commercial strategy intended to drive market share growth without sacrificing revenue.
Donn Casale, President and CEO of ARS Pharma
Our confidence in continued revenue growth, along with a more efficient commercial model, is expected to provide the foundation for long-term value creation.
Donn Casale, President and CEO of ARS Pharma
There is a solid foundation in place, growing prescriber momentum, and a talented field organization.
Meg Smith, Chief Commercial Officer
Not in the filing
stated, not guessed- Gross profit
- Gross margin
- Non-GAAP revenue, earnings, operating income, net income, or EPS measures
- Operating cash flow
- Free cash flow
- Share repurchases
- Dividends
- Revenue guidance
- Gross-margin guidance
- Tax-rate guidance
- Prior-quarter comparisons for reported income-statement metrics
- Prior-quarter guidance or previous quarterly outlook for comparison
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
The filing is an SEC 8-K (Item 2.02) with an earnings-style release (Exhibit 99.1) covering strategic priorities, commercial metrics for neffy, and financial results for the quarter ended June 30, 2026.
Ticker impact
ARS Pharmaceuticals reported Q2 2026 results and updated 2H 2026 SG&A and R&D expense guidance, plus a CSU Phase 2b interim-data timeline.
Moderate volatility possible around the after-hours conference call and any follow-through on the updated expense path and CSU interim-data expectations.
This is a primary filing with multiple new datapoints (Q2 financials, cash balance, expense range for 2H 2026, CCO appointment, and CSU interim-data timing). However, it does not include FDA action or new Phase 2b efficacy results, limiting upside/downside magnitude.
Market effects
Reinforces the commercialization-and-cost-discipline playbook for small-cap specialty pharma, with intranasal epinephrine and CSU as the key pipeline narrative.
Limited direct regional spillover; primarily affects US small-cap biotech sentiment.
Low global relevance beyond specialty allergy and acute CSU treatment expectations.
Counterpoint
Despite revenue growth and expense guidance, the company still reports a very large net loss and provides only a timeline for CSU interim data, not new clinical efficacy.
Key entities
- companyARS Pharmaceuticals, Inc.
Subject of the 8-K, reporting Q2 2026 financial results, commercial metrics for neffy, and updated 2H 2026 expense guidance.
- productneffy (epinephrine nasal spray)
Company’s needle-free epinephrine offering; the release highlights US net product revenue and market share gains.
- executiveMeg Smith
Appointed Chief Commercial Officer effective Aug 17, 2026, with prior commercial launch experience at Dynavax.
- clinical_programPhase 2b trial in chronic spontaneous urticaria (CSU)
Interim data expected in Q1 2027; no FDA-approved on-demand acute CSU treatment currently exists per the release.
